MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$77,426K
Net cash provided by
(used in) financing...
$77,426K
Net increase in
cash, cash...
$11,294K
Canceled cashflow
$66,132K
Increase (decrease) in
accrued expenses
$11,390K
Stock-based compensation
expense
$6,288K
Decrease in operating
lease right-of-use...
-$1,051K
Decrease (increase) in
prepaid expenses and...
-$634K
Depreciation expense
$233K
Proceeds from sales and
maturities of investments
$161,457K
Net cash used in
operating activities
-$64,491K
Net cash used in
investing activities
-$1,641K
Canceled cashflow
$19,596K
Canceled cashflow
$161,457K
Net loss
-$78,537K
Purchases of investments
$163,091K
(decrease) increase in
accounts payable
-$2,349K
Decrease in operating
lease liabilities
-$1,606K
Net amortization of
premiums and discounts on...
$1,366K
Other
$229K
Purchases of property and
equipment
$7K
Back
Back
Cash Flow
source: myfinsight.com
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)